The financing was realized with a pool of industrial and independent investors:
• Two industrial groups: Lauak, making its first investment since creation outside the aeronautics sector, and Doliam, a specialist in implantable medical components and devices.
• FineHeart Founders’ Holding, brings together international private investors, mainly from the cardiology sector, and the pan-European investor network Verve Ventures. They join historical shareholders Irdi, Aquiti, Galia, Broadview Ventures, and M Capital, who have renewed their support for FineHeart.

“I am delighted to have completed this financing with such a complimentary pool of investors who are committed to FineHeart’s long-term growth and who share our ambition to become a new name worldwide in medical devices for cardiology,” said Arnaud Mascarell, CEO and Cofounder FineHeart. “This consortium of shareholders represents a new approach, going beyond straightforward financial support. We have brought together know-how from the world of technological excellence and renowned medical expertise, shown by the substantial contribution from cardiologists, who have individually invested through the FineHeart Founders Holding Company. I am extremely grateful for their support, and I reiterate our determination to deliver the disruptive treatment that the ICOMS FLOWMAKER® represents.”

This financing operation is a significant achievement for FineHeart in the run-up to clinical trials. The ICOMS FLOWMAKER® has successfully accomplished all the key milestones prior to First-In-Human trials. The international medical community welcomed these preclinical trial results as an efficient solution to treat severe heart failure, thus
validating the potential for the ICOMS FLOWMAKER® as an effective treatment.

Read our interview with the renowned heart surgeon Thierry Carrel here.

Why we’ve invested in FineHeart:

Current methods to treat heart failure require the opening of the chest to place the pumps. Many weak patients die during the procedure. Those who survive will have cables dangling out of their bodies that connect the pump to an external power source. This is not only impractical but also a source of infections.

FineHeart was founded in 2010 by a team of internationally renowned cardiac surgeons and cardiologists to find a better solution. The pump is unique because it is the first permanent pump that is inserted directly inside the heart, is wirelessly charged and can be installed into the heart during a minimally invasive surgery. The device is much smaller than existing solutions and works as a mini, and smart turbine which can be adjusted, depending on the severity of heart failure, to modify a patient’s blood flow.

FineHeart’s approach has received significant interest and world-renowned key opinion leaders have joined their board of advisors, e.g. Michael Acker, the chief of cardiac surgery at Penn Medicine, Mandeep Mehra, Director of research on Heart Failure at Harvard Medical School, and Frank Pagani, Surgical Director of the Adult Heart Transplant, Michigan Medicine.